Biology of Blood and Marrow Transplantation
Volume 14, Issue 7 , Pages 766-774, July 2008

Evaluation of Angiopoietins and Cell-Derived Microparticles after Stem Cell Transplantation

  • Shosaku Nomura

      Affiliations

    • Division of Hematology, Kishiwada City Hospital, Osaka, Japan
    • Corresponding Author InformationCorrespondence and reprint requests: Shosaku Nomura, MD, Division of Hematology, Kishiwada City Hospital, 1001, Gakuhara-cho, Kishiwada, Osaka 596-8501, Japan.
  • ,
  • Kazuyoshi Ishii

      Affiliations

    • Division of Hematology, Kishiwada City Hospital, Osaka, Japan
  • ,
  • Norihito Inami

      Affiliations

    • Second Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, Japan
  • ,
  • Yutaka Kimura

      Affiliations

    • Second Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, Japan
  • ,
  • Nobuhiko Uoshima

      Affiliations

    • Department of Internal Medicine, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan
  • ,
  • Hiroyuki Ishida

      Affiliations

    • Department of Pediatrics, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan
  • ,
  • Takao Yoshihara

      Affiliations

    • Department of Pediatrics, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan
  • ,
  • Fumiaki Urase

      Affiliations

    • Department of Hematology, Kinki University, Sayama, Osaka, Japan
  • ,
  • Yasuhiro Maeda

      Affiliations

    • Department of Hematology, Kinki University, Sayama, Osaka, Japan
  • ,
  • Kunio Hayashi

      Affiliations

    • Division of Hematology, Keihanna Hospital, Hirakata, Osaka, Japan

Received 3 February 2008; accepted 10 April 2008.

Abstract 

Although stem cell transplantation (SCT) is being used for hematopoietic reconstitution following high-dose chemotherapy for malignancy, it involves certain serious transplant-related complications such as graft-versus-host disease (GVHD). Angiopoietins play important roles in angiogenesis. However, the role of angiopoietins after SCT is poorly understood. In this study, 52 patients underwent SCT; 26 patients received allogeneic SCT, while the remaining 26 received autologous SCT. In 48 of 52 patients, levels of angiopoietins, cytokines, and soluble factors were measured by enzyme-linked immunosorbent assay. Soluble Fas ligand (sFasL) and endothelial cell-derived microparticle (EDMP) exhibited significant elevation in the early phase (2-3 weeks) after SCT. In addition, the elevation of interleukin (IL)-6, tumor necrosis factor (TNF)-α, and sIL-2 receptor (sIL-2R), which are GVHD markers after allogeneic SCT was observed. The level of angiopoietin (Ang)-2 in allogeneic SCT continued to increase for up to 4 weeks, although the level of Ang-1 did not show significant changes. The patients with high Ang-2 exhibited significant increase of sFasL and EDMP compared with those with low Ang-2. In addition, the patients with high-grade GVHD exhibited a significant increase in Ang-2 compared to patients with low-grade GVHD. In the in vitro experiment using endothelial cells, the suppressive effect of Ang-1 on EDMP generation by TNF-α was partially inhibited by the addition of Ang-2. Furthermore, multivariate regression analysis showed that EDMP and sFasL were significant factors in Ang-2 elevation. Our results suggest that Ang-2 generation after allogeneic SCT relates to GVHD.

Key Words: Angiopoietin, GVHD, stem cell transplantation, sFas, endothelial cell-derived microparticle

 

PII: S1083-8791(08)00149-3

doi:10.1016/j.bbmt.2008.04.005

Biology of Blood and Marrow Transplantation
Volume 14, Issue 7 , Pages 766-774, July 2008